Daiichi
Biotech

How Daiichi Sankyo plans to stay ahead in the ADC game

For Daiichi and its new head of R&D, the challenge is about outrunning the very ADC gold rush the company helped ignite.
Angus Liu Jun 17, 2026 6:00pm
A graphic symbolizing one group acquiring another

Biogen inks $1B RayThera buyout to bag immunology assets

Jun 18, 2026 4:10am
FDA

Moderna’s flu candidate sails through FDA adcomm

Jun 18, 2026 3:03pm
field plow tractor wheat farm dust row plant grow

cAMPfield harvests $180M series A to advance oral IBD asset

Jun 18, 2026 10:34am
pills oral bottle medicine therapy drug

Nortiva purrs into action with long-acting Lynx platform

Jun 18, 2026 8:00am
IPO initial public offering

UPDATED: Kardigan buttons up $400M upsized IPO for phase 3 push

Jun 18, 2026 7:28am
More News

F2G, Shionogi prep regulatory push after antifungal passes ph. 3

Jun 18, 2026 12:01am

Vedana surfaces with $46M to develop migraine prevention therapies

Jun 17, 2026 9:48am

Fierce Biotech Fundraising Tracker '26: Triveni Bio & more

Jun 17, 2026 9:30am

UniQure stock surges after FDA U-turn clears path to filing

Jun 17, 2026 9:10am